Japan Vaccines Market Overview, 2028

Japan Vaccines Market Overview, 2028

Japanese culture places a significant emphasis on preventive healthcare. People are encouraged to maintain a healthy lifestyle through balanced nutrition, regular exercise, and stress management to prevent illness. Japan has a rapidly ageing population, and there is a strong cultural tradition of respecting and caring for elderly family members. Many families take on the responsibility of caring for their elderly parents or grandparents at home. Vaccine hesitancy has been a notable feature of Japan's vaccine culture. In the past, concerns about vaccine safety, particularly those related to adverse events, led to a decline in vaccination rates for certain diseases like measles, mumps, and rubella (MMR). This hesitancy was fueled by media reports and public anxiety. The incident in the late 1980s involving the MMR vaccine and cases of aseptic meningitis in Japan significantly eroded public trust in vaccines. Subsequently, Japan suspended the MMR vaccine from its routine vaccination schedule, leading to outbreaks of these diseases. The country has a rigorous vaccine approval process. While this process ensures high standards of vaccine safety and efficacy, it can also contribute to delays in introducing new vaccines to the market. In response to vaccine hesitancy and disease outbreaks, the Japanese government has launched public awareness campaigns to rebuild trust in vaccines. These campaigns aim to educate the public about the importance of vaccination and dispel misconceptions. In recent years, Japan has introduced stricter school vaccination requirements to improve vaccine coverage among school-age children. These requirements help protect the population from vaccine-preventable diseases. Japan's universal healthcare system ensures that vaccines are accessible and affordable for all citizens. This contributes to overall vaccine coverage and public health.

According to the research report ""Japan Vaccines Market Overview, 2028,"" published by Bonafide Research, the Japan Vaccines market is expected to reach a market size of more than USD 4 Billion by 2028. The Japanese government has implemented various initiatives to improve vaccination rates, including stricter school vaccination requirements and increased accessibility to vaccines. These efforts aim to ensure that a larger portion of the population is up to date on their vaccinations. Travel-related vaccines have gained importance as international travel has become more common among Japanese citizens. People often seek vaccinations when travelling abroad to protect themselves from diseases prevalent in other regions. The economic impact of vaccine-preventable diseases, such as missed workdays and healthcare costs, has prompted some individuals and employers to prioritise vaccination. The government recommends and sometimes mandates certain vaccines, especially for schoolchildren. These recommendations and requirements play a significant role in driving vaccine demand. Routine health check-ups and screenings are common in Japan, and vaccines are often included in these preventive healthcare measures, leading to higher vaccine demand. Japan has a rapidly ageing population, and older adults are more susceptible to certain vaccine-preventable diseases. This demographic trend drives demand for vaccines targeting diseases more common among older adults, such as influenza and pneumonia. Japanese citizens travelling abroad often require vaccines to protect themselves from diseases prevalent in other regions. This has led to increased demand for travel vaccines. Japan has introduced stricter school vaccination requirements to improve vaccine coverage among school-age children, which helps protect the population from vaccine-preventable diseases. The economic impact of vaccine-preventable diseases, such as missed workdays and healthcare costs, has prompted some individuals and employers to prioritise vaccination.

Based on the route of administration, they are segmented into intramuscular and subcutaneous administration, oral administration, and others. In Japan, intramuscular and subcutaneous vaccinations lead the vaccine market as the routes of administration. Japan has a robust routine immunisation programme that includes a schedule of vaccinations for various age groups. Many vaccines in the programme are traditionally administered via IM or SC injection. Certain vaccines, such as those for diphtheria, tetanus, pertussis, polio, and hepatitis B, are designed for IM or SC administration. These vaccines protect against diseases that are part of Japan's recommended vaccination schedule. Japan has a well-developed healthcare infrastructure with trained healthcare professionals who can administer vaccines effectively through IM and SC injections. This infrastructure supports efficient vaccine delivery. According to the report, types are segmented into multivalent vaccines and monovalent vaccines, among them. In this country, multivalent vaccines are the leading market. Multivalent vaccines combine protection against multiple diseases into a single vaccine, reducing the number of shots needed. This simplification is particularly advantageous for children and adolescents, as it minimises the discomfort and inconvenience associated with multiple injections. Japan has a relatively high population density, and healthcare resources are efficiently utilised through the use of combination vaccines, which require fewer healthcare visits and syringes. Japan's national immunisation programme includes a comprehensive schedule of vaccines for children, including multivalent vaccines. These vaccines protect against diseases like diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B (Hib), and hepatitis B.

In terms of disease types, they include the rotavirus, pneumococcal diseases, cancer, influenza, diphtheria, pertussis, and tetanus, the human papilloma virus (HPV), hepatitis, shingles, meningococcal diseases, varicella, mumps, and others. In Japan, hepatitis is increasing the demand for vaccines in the country. Hepatitis B virus (HBV) infection has been a significant public health concern in Japan, with certain regions having relatively high prevalence rates. Chronic hepatitis B can lead to serious liver diseases, including cirrhosis and liver cancer, making vaccination a critical strategy for disease prevention. Japan has included hepatitis B vaccination as part of its national immunisation program. This programme targets infants and adolescents, aiming to provide immunity early in life and reduce the risk of HBV transmission. Japan's healthcare system emphasises the importance of early diagnosis and vaccination against hepatitis B, especially among high-risk populations. Healthcare providers actively screen individuals for HBV infection and offer vaccination as a preventive measure. Certain professions in Japan, such as healthcare workers, may be at higher risk of exposure to hepatitis B. Occupational vaccination programmes are in place to protect these individuals. Some hepatitis B vaccines are included in combination vaccines, such as the pentavalent vaccine, which also protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B (Hib). This simplifies the vaccination schedule and increases the coverage rate.

Japan has one of the world's largest and fastest-ageing populations. This demographic trend presents an opportunity for vaccine manufacturers to develop and market vaccines targeting diseases more common among older adults, such as influenza, pneumonia, and shingles. Japan has a high healthcare expenditure per capita. As the population continues to age and healthcare needs increase, there is a growing demand for healthcare services, including vaccines. The Japanese government actively supports vaccination programmes through funding, recommendations, and mandates. Government initiatives can drive increased demand for vaccines. Japan's commitment to global health initiatives positions the country as a key player in international vaccination efforts. This involvement can lead to collaborations and opportunities in vaccine research, development, and distribution. Historically, vaccine hesitancy has been a challenge in Japan, especially following adverse events related to certain vaccines. Addressing vaccine hesitancy through public education campaigns remains a priority. Japan has a stringent vaccine approval process, which can lead to delays in introducing new vaccines to the market. This process can be challenging for vaccine manufacturers. The global vaccine market is competitive, and Japanese manufacturers may face competition from multinational pharmaceutical companies.

Based on the technology, it is segmented into conjugate vaccines, inactivated and subunit vaccines, live-attenuated vaccines, recombinant vaccines, and toxoid vaccines. In Japan, the toxoid vaccine market is growing with a significant market share. Japan has a very high vaccination rate for toxoid vaccines, such as the diphtheria-tetanus-pertussis (DTaP) vaccine. This is due to a number of factors, including government support for vaccination programmes, high public awareness of the importance of vaccination, and the strong trust that the Japanese people have in their healthcare system. Japanese citizens are travelling more frequently than ever before, and this is increasing the risk of exposure to diseases such as diphtheria and tetanus, which are still common in some parts of the world. This is also driving demand for toxoid vaccines in Japan. New toxoid vaccines are being developed, such as the combination DTaP-inactivated poliovirus vaccine (DTaP-IPV). These new vaccines are expected to boost demand for toxoid vaccines in Japan. The Japanese government provides financial support to manufacturers of toxoid vaccines, and this is helping to drive the growth of the market. The Japanese government and other organisations run public awareness campaigns to educate the public about the importance of toxoid vaccines. This is also helping to drive the growth of the market.

According to the report, the end user is segmented into adult and paediatric. In Japan, paediatrics is the leading end user of Vaccines. Japan has well-established routine childhood vaccination programmes that recommend and often require vaccines for infants and young children. These programmes include vaccines against diseases such as measles, mumps, rubella, diphtheria, pertussis, tetanus, and more. Paediatricians are the primary healthcare providers responsible for administering these vaccines. Japanese schools, both public and private, often have vaccination requirements for students. Children must provide proof of vaccination or immunity to certain diseases before attending school. This ensures that a large portion of the paediatric population receives the recommended vaccines. There is a strong cultural emphasis on child health in Japan, with parents and the government prioritising the well-being of children. Preventive healthcare, including vaccination, is seen as a crucial aspect of child health. Japan has a well-developed healthcare infrastructure with a network of paediatric clinics and hospitals that specialise in child healthcare. Parents have easy access to healthcare services for their children, including vaccinations.

Distribution channels include hospital pharmacy, retail pharmacy, institutional sales, and others. In Japan, hospital pharmacy is a growing market, and all residents have access to healthcare thanks to the country's universal healthcare system. The foundation of this system and the main source of medical treatment are hospitals. Vaccinations are frequently given to patients while they are in the hospital, guaranteeing widespread immunisation coverage. Hospitals are staffed with trained healthcare professionals, including doctors and nurses, who have the expertise to administer vaccines safely and effectively. This expertise instills confidence in patients and their families. Hospitals play a crucial role in administering vaccines as part of routine childhood vaccination programs. Children often receive their scheduled vaccinations during well-baby check-ups and other paediatric visits to hospitals. Hospitals have the necessary infrastructure and equipment to store vaccines at the recommended temperatures, ensuring the vaccines' efficacy and safety. Furthermore, the healthcare system in Japan maintains high standards of quality and safety, which extend to vaccine distribution and administration in hospitals and pharmacies.

Considered in this report:
• Geography: Japan
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• Japan Vaccines market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines
• Viral vector vaccines
• Others

By Route of Administration
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

By Disease
• Rotavirus
• Pneumococcal diseases
• Cancer
• Influenza
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Hepatitis
• Shingles
• Meningococcal diseases
• Varicella (Chicken Pox)
• Mumps
• Others

By Type
• Multivalent vaccines
• Monovalent vaccines

By End-User Type
• Paediatrics
• Adults

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.